DECIPHERA PHARMACEUTICALS, INC.

(DCPH)
  Report
Delayed Nasdaq  -  04:00 2022-08-12 pm EDT
16.41 USD   +4.06%
08/10Deciphera Pharmaceuticals, Inc. Announces Publication of INTRIGUE Phase 3 Clinical Study Results in Journal of Clinical Oncology
BU
08/10Deciphera Pharmaceuticals, Inc. Announces Publication of Intrigue Phase 3 Clinical Study Results in Journal of Clinical Oncology
CI
08/05HC Wainwright Adjusts Price Target on Deciphera Pharmaceuticals to $20 From $15, Reiterates Buy Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Earnings Flash (DCPH) DECIPHERA PHARMACEUTICALS Posts Q1 Revenue $29.2M, vs. Street Est of $27.2M

05/04/2022 | 07:04am EDT


© MT Newswires 2022
All news about DECIPHERA PHARMACEUTICALS, INC.
08/10Deciphera Pharmaceuticals, Inc. Announces Publication of INTRIGUE Phase 3 Clinical Stud..
BU
08/10Deciphera Pharmaceuticals, Inc. Announces Publication of Intrigue Phase 3 Clinical Stud..
CI
08/05HC Wainwright Adjusts Price Target on Deciphera Pharmaceuticals to $20 From $15, Reiter..
MT
08/05JMP Securities Upgrades Deciphera Pharmaceuticals to Market Outperform From Market Perf..
MT
08/04Piper Sandler Adjusts Deciphera Pharmaceuticals Price Target to $13 From $11, Maintains..
MT
08/04Deciphera Pharmaceuticals' Q2 Loss Narrows, Revenue Rises
MT
08/04TRANSCRIPT : Deciphera Pharmaceuticals, Inc., Q2 2022 Earnings Call, Aug 04, 2022
CI
08/04DECIPHERA PHARMACEUTICALS : Announces Second Quarter 2022 Financial Results - Form 8-K
PU
08/04DECIPHERA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Cond..
AQ
08/04Earnings Flash (DCPH) DECIPHERA PHARMACEUTICALS Posts Q2 Revenue $32.5M
MT
More news
Analyst Recommendations on DECIPHERA PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 129 M - -
Net income 2022 -176 M - -
Net cash 2022 190 M - -
P/E ratio 2022 -6,56x
Yield 2022 -
Capitalization 1 097 M 1 097 M -
EV / Sales 2022 7,01x
EV / Sales 2023 5,84x
Nbr of Employees 280
Free-Float 72,4%
Chart DECIPHERA PHARMACEUTICALS, INC.
Duration : Period :
Deciphera Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DECIPHERA PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 16,41 $
Average target price 15,38 $
Spread / Average Target -6,31%
EPS Revisions
Managers and Directors
Steven L. Hoerter President & Chief Executive Officer
Thomas P. Kelly Chief Financial Officer, Treasurer & Executive VP
James A. Bristol Chairman
Daniel L. Flynn President, Chief Executive Officer & Director
Stephen B. Ruddy Chief Technical Officer & SVP
Sector and Competitors
1st jan.Capi. (M$)
DECIPHERA PHARMACEUTICALS, INC.67.96%1 097
GILEAD SCIENCES, INC.-13.29%78 912
VERTEX PHARMACEUTICALS34.12%75 532
REGENERON PHARMACEUTICALS, INC.-0.45%67 214
WUXI APPTEC CO., LTD.-20.10%40 830
BIONTECH SE-37.80%38 968